Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

Emphasizing its commitment to low-dose medical imaging, GE Healthcare today announced 510(k) clearance of its revolutionary Computed Tomography (CT) technology, called Veo,* which may help physicians deliver accurate diagnoses by enabling profound CT image clarity at dramatically lower dose. Veo represents the CT industry’s first Model-based Iterative Reconstruction (MBIR) technique, and is already available on GE Discovery CT750 HD systems in Europe, Canada and regions of Asia.

20 Sep 2011

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator.

20 Sep 2011

UNC researchers develop technique that can observe cellular intricacies of CF

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.

20 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Following some basic rules of central line hygiene and maintenance, Johns Hopkins Children's Center and 87 other pediatric hospitals have, over five years, saved hundreds of patient lives and more than $100 million by preventing nearly 3,000 central line bloodstream infections, hospital officials announced on Monday, Sept. 12.

16 Sep 2011

Estrogen therapy can reverse progression of pulmonary hypertension

UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart failure.

16 Sep 2011

Scientists uncover unknown fail-safe pathway for inherited disorders

Scientists at the University of California, San Diego School of Medicine have uncovered a previously unknown fail-safe (compensatory) pathway that potentially protects the brain and other organs from genetic and environmental threats.

16 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.

14 Sep 2011

InterMune to launch Esbriet for German patients with IPF

InterMune, Inc. today announced that Esbriet will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available in Europe since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a devastating and fatal lung disease.

12 Sep 2011

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

9 Sep 2011

Abnormal levels of lysophosphatidic acid can trigger congenital hydrocephalus

Scientists at The Scripps Research Institute have found what may be a major cause of congenital hydrocephalus, one of the most common neurological disorders of childhood that produces mental debilitation and sometimes death in premature and newborn children.

8 Sep 2011

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

The American Physiological Society is sponsoring the 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels, being held September 18-22 at the Asilomar Conference Grounds in Pacific Grove, Calif. This scientific conference explores the connection between fluid balance in the body and hypertension, a growing global health concern.

8 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Loyola surgeons use new, less invasive catheter technique to treat cystic fibrosis

Cystic fibrosis patient Daniel Sammons had undergone a successful double lung transplant at Loyola University Medical Center, but he still had one major health issue.

3 Sep 2011

PTC restructures collaboration with Genzyme

PTC Therapeutics, Inc. and Genzyme, a Sanofi company, announced today the restructuring of their collaboration. Under the original agreement, PTC held commercial rights for the U.S. and Canada and Genzyme held commercial rights in all other countries.

2 Sep 2011

Freiburg researchers receive European Research Council Starting Grants

Marta Artal Sanz, Thomas Brox, Winfried Römer, and Oliver Schilling from the University of Freiburg have been selected for one of the most prestigious European grants for young researchers: The European Research Council (ERC) has awarded them a total of 5.8 million euros in ERC Starting Grants for new projects.

2 Sep 2011

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

Hollywood, Health & Society, a program of the Norman Lear Center at the University of Southern California (USC) Annenberg School for Communication & Journalism and the Centers for Disease Control and Prevention (CDC), are announcing eight finalists for the Sentinel for Health Awards.

29 Aug 2011

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio Corporation announced today that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication.

25 Aug 2011

Fibrosis News and Research

Further Reading

GE Healthcare unveils ultra-low dose CT technology with profound image clarity

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

UNC researchers develop technique that can observe cellular intricacies of CF

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Simple strategies prevent bloodstream infections and save hundreds of patient lives

Estrogen therapy can reverse progression of pulmonary hypertension

Scientists uncover unknown fail-safe pathway for inherited disorders

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

InterMune to launch Esbriet for German patients with IPF

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Abnormal levels of lysophosphatidic acid can trigger congenital hydrocephalus

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Loyola surgeons use new, less invasive catheter technique to treat cystic fibrosis

PTC restructures collaboration with Genzyme

Freiburg researchers receive European Research Council Starting Grants

HH&S, CDC announce eight finalists for 2011 Sentinel for Health Awards

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News